A Phase 1 Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Intravenous Dose Study of VGL 101
Latest Information Update: 15 Jun 2023
At a glance
- Drugs Iluzanebart (Primary)
- Indications Neurodegenerative disorders
- Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
- Sponsors Vigil Neuroscience
- 27 Apr 2023 Results (n=74; to date) reporting safety, PK and PD profiles presented at the 75th Annual Meeting of the American Academy of Neurology 2023
- 18 Aug 2021 According to a Vigil Neuroscience media release, the company expect to initiate this study by year end 2021.
- 15 Dec 2020 New trial record